Drug intelligence / Profile preview

TS-2021

Development stage: Phase 1
Lead developer: Beijing Neurosurgical Institute
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

TS-2021 is an oncolytic virus being investigated for the treatment of recurrent malignant glioma. The therapy is administered via intratumoral injection directly into the tumor site. Clinical trials are currently evaluating its safety and efficacy in patients with recurrent malignant glioma, including glioblastoma multiforme.

Targets

TGFB2 (Transforming growth factor beta 2)

Beyond the preview

Go deeper on TS-2021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TS-2021.